In a visit to Lif, Jesper Fisker (CEO, Danish Cancer Society) warned that the US “most favored nation” (MFN) policy could have consequences for Denmark if Denmark is increasingly used as a reference country for US medicine prices.

Fisker said this could directly affect Danish patients and called for a national Danish solution. In his words, the risk is that Danish patients may not get the best medicines fast enough.

Key points:

• MFN: Fisker calls for a national solution, otherwise it will affect patients.

Read more at https://www.lif.dk/jesper-fisker-most-favored-nation-maa-ikke-gaa-ud-over-danske-patienter/

Indlægget Danish Cancer Society warns MFN could slow access in Denmark blev først udgivet på NHTA.